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Background
Hypertrophic cardiomyopathy (HCM) is the most com-
mon inheritable heart disease, characterized by marked
left ventricular hypertrophy in the absence of a disease
that can cause hypertrophy to such extent. Both LV
ejection fraction (EF) and LV mass have proven to be
prognosticators in HCM.
The literature is inconsistent with respect to in- or
exclusion of papillary muscles (PMs) to LV-mass, which
might influence volumetric results. PMs might be part
of the hypertrophic process and substantially contribute
to LV mass.
We investigated the impact of in- and exclusion of the
P M st oL Vm a s si nt h ea s s e s s m e n to fp r o g n o s t i cL V
parameters in HCM.
Methods
Three groups of subjects were included:
1) HCM patients: phenotype +, genotype + (n = 27)
2) HCM patients: phenotype +, genotype - (n = 36)
3) preclinical HCM mutation carriers: phenotype -,
genotype + (n = 10).
Standard cineMRI was performed with 10 mm short-
axis slices; images were analyzed, epi- and endocardial
and PM contours were manually drawn. LV volumes
and mass were calculated with and without the inclusion
of PMs to the LV mass. Volumes and mass obtained
with and without inclusion of PMs were compared
using paired samples t-test. Pearson’s correlation coeffi-
cient was used to investigate whether PMs mass is
related to LV mass.
Results
Inclusion of PMs to the LV mass, resulted in a signifi-
cant reduction in LV volumes and an increase in EF
(Table 1). PMs-mass for group 1, 2 and 3 was 5.8±1.5 g/
m2, 6.8±3.0 g/m2 and 3.9±0.9 g/m2, respectively. The
relative contribution of the PMs mass to the absolute
LV mass did not differ between groups. However, PMs
mass was associated with absolute LV mass in group 1
and 2, r=0.639 (p<.001) and r=0.800 (p<.001), respec-
tively, but not in group 3.
Conclusions
Inclusion of the papillary muscles to the LV mass signif-
icantly changes LV volumes and ejection fraction, in
both patients with HCM and preclinical individuals
without hypertrophy. Given the prognostic impact of
both ejection fraction and LV mass, our data underscore
the importance of standardized assessment either with
or without inclusion of the papillary muscles to the LV
mass.
Given the association between LV mass and papillary
muscle mass in patients with HCM, the clinical conse-
quences of assessment with uniform in- or exclusion
remains to be determined.
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Table 1 Impact of in- or exclusion of the papillary
muscles to LV mass on LV volumes, mass and EF.
Group 1 (Phenotype+ Genotype+)(n =27)
Exclusion Inclusion P=
LV EDV (ml/m2) 96.9±15.5 91.4±14.8 <.001
LV ESV(ml/m2) 41.5±13.3 36.9±12.8 <.001
LV EF (%) 57.9±7.2 60.3±7.6 <.001
LV Mass (g/m2) 71.9±23.1 77.8±24.1 <.001
Group 2 (Phenotype+ Genotype-)(n = 36)
Exclusion Inclusion P=
LV EDV (ml/m2) 90.9±15.5 84.4±13.9 <.001
LV ESV(ml/m2) 37.6±9.9 32.6±8.6 <.001
LV EF (%) 58.8±7.2 61.5±7.5 <.001
LV Mass (g/m2) 78.3±32.0 85.2±34.5 <.001
Group 3(Phenotype- Genotype+)(n = 10)
Exclusion Inclusion P=
LV EDV (ml/m2) 91.5±9.5 87.8±9.3 <.001
LV ESV(ml/m2) 37.1±7.9 33.7±7.9 <.001
LV EF (%) 59.8±6.0 62.0±6.5 <.001
LV Mass (g/m2) 43.2±10.7 47.0±11.3 <.001
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